The acceptability and feasibility of large-scale testing with lateral flow tests (LFTs) for clinical
and public health purposes has been demonstrated during the COVID-19 pandemic. LFTs …

The COVID-19 pandemic has challenged the conventional diagnostic field and revealed the
need for decentralized Point of Care (POC) solutions. Although nucleic acid testing is …

Deployment of nucleic acid amplification assays for diagnosing pathogens in point-of-care
settings is a challenge due to lengthy preparatory steps. We present a molecular diagnostic …

Nucleic acid detection methods based on CRISPR and isothermal amplification techniques
show great potential for point-of-care diagnostic applications. However, most current …

Pathogenic biosafety is a worldwide concern. Tools for analyzing pathogenic biosafety, that
are precise, rapid and field-deployable, are highly demanded. Recently developed …

Nucleic acids in biofluids are emerging biomarkers for the molecular diagnostics of
diseases, but their clinical use has been hindered by the lack of sensitive detection assays …

Mass pathogen screening is critical to preventing the outbreaks and spread of infectious
diseases. The large‐scale epidemic of COVID‐19 and the rapid mutation of the severe acute …

An increasingly pressing need for clinical diagnostics has required the development of novel
nucleic acid-based detection technologies that are sensitive, fast, and inexpensive, and that …

Accurate diagnosis of human diseases is crucial for effective prevention, clinical treatment,
and prognosis. The World Health Organization (WHO) has provided guidelines for molecular …

Biosensing based on CRISPR-Cas systems is a young but rapidly evolving technology. The
unprecedented properties of the CRISPR-Cas system provide an innovative tool for …